CN111372598A - 使用消除衰老细胞的药剂治疗诸如黄斑变性,青光眼,和糖尿病性视网膜病变等眼科状况 - Google Patents

使用消除衰老细胞的药剂治疗诸如黄斑变性,青光眼,和糖尿病性视网膜病变等眼科状况 Download PDF

Info

Publication number
CN111372598A
CN111372598A CN201880063962.8A CN201880063962A CN111372598A CN 111372598 A CN111372598 A CN 111372598A CN 201880063962 A CN201880063962 A CN 201880063962A CN 111372598 A CN111372598 A CN 111372598A
Authority
CN
China
Prior art keywords
eye
condition
cells
disease
ophthalmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880063962.8A
Other languages
English (en)
Chinese (zh)
Inventor
J·霍普金斯
P·苏鲁达
C·查普曼
H·斯威加德
Y·潘
D·马克斯
N·大卫
J·达南伯格
R-M·雷伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Barker Institute Of Aging
United Biotechnology
Original Assignee
Barker Institute Of Aging
United Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/675,171 external-priority patent/US20180000816A1/en
Application filed by Barker Institute Of Aging, United Biotechnology filed Critical Barker Institute Of Aging
Publication of CN111372598A publication Critical patent/CN111372598A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880063962.8A 2017-08-11 2018-08-13 使用消除衰老细胞的药剂治疗诸如黄斑变性,青光眼,和糖尿病性视网膜病变等眼科状况 Pending CN111372598A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15/675,171 2017-08-11
US15/675,171 US20180000816A1 (en) 2015-02-06 2017-08-11 Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
US201762579793P 2017-10-31 2017-10-31
US62/579,793 2017-10-31
PCT/US2018/046553 WO2019033119A1 (en) 2017-08-11 2018-08-13 TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS

Publications (1)

Publication Number Publication Date
CN111372598A true CN111372598A (zh) 2020-07-03

Family

ID=63254539

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880063962.8A Pending CN111372598A (zh) 2017-08-11 2018-08-13 使用消除衰老细胞的药剂治疗诸如黄斑变性,青光眼,和糖尿病性视网膜病变等眼科状况

Country Status (7)

Country Link
EP (2) EP4234025A3 (https=)
JP (2) JP7278257B2 (https=)
CN (1) CN111372598A (https=)
AU (2) AU2018314280B2 (https=)
CA (1) CA3072673A1 (https=)
MX (2) MX2020001644A (https=)
WO (1) WO2019033119A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115568281A (zh) * 2021-05-04 2023-01-03 福森生物科技有限公司 一种含有咪唑啉衍生物化合物作为有效成分的用于治疗黄斑变性的药物组合物
WO2024051741A1 (zh) * 2022-09-06 2024-03-14 西藏海思科制药有限公司 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200354336A9 (en) 2017-08-11 2020-11-12 Unity Biotechnology, Inc. Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells
US10588916B2 (en) 2017-10-31 2020-03-17 Unity Biotechnology, Inc. Technology to inhibit vascular changes that lead to vision loss in the eye
CN117866015A (zh) 2018-04-30 2024-04-12 联合生物科技公司 一种临床管理中使用的化合物及其用途
US10717722B2 (en) 2018-06-13 2020-07-21 Unity Biotechnology, Inc. Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
CN113528510A (zh) 2018-06-29 2021-10-22 武汉纽福斯生物科技有限公司 治疗遗传性视神经病变的组合物和方法
SG11202101032VA (en) * 2018-08-20 2021-02-25 Wuhan Neurophth Biotechnology Ltd Company Compositions and methods for treating leber's hereditary optic neuropathy
MX2022003027A (es) * 2019-09-13 2022-06-14 The Us Secretary Department Of Health & Human Services Diana susceptible a modularse por farmacos para tratar degeneracion retiniana.
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
EP4146218A4 (en) * 2020-05-04 2024-08-28 Ascentage Pharma (Suzhou) Co., Ltd. METHODS OF TREATING CORONAVIRUS INFECTIONS
JP2024501033A (ja) * 2020-12-28 2024-01-10 エムディー ヘルスケア インコーポレイテッド ミクロコッカス・ルテウス由来細胞外小胞を含む眼疾患の予防または治療用組成物
EP4301374A4 (en) 2021-03-01 2025-09-10 Deciduous Therapeutics Inc COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS
CA3215235A1 (en) * 2021-04-13 2022-10-20 Sharon KLIER Methods of treating retinal vasculopathies
WO2025009608A1 (ja) * 2023-07-06 2025-01-09 学校法人自治医科大学 生体内物質又は薬物の生体内半閉鎖系における濃度調節剤
CN119925379B (zh) * 2025-03-05 2025-09-05 中南大学湘雅医院 Bcl3抑制剂在制备治疗青光眼的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012103059A2 (en) * 2011-01-25 2012-08-02 The Regents Of The University Of Michigan Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
WO2014113413A1 (en) * 2013-01-16 2014-07-24 The Regents Of The University Of Michigan Bcl-2bcl-xl inhibitors and therapeutic methods using the same
WO2016127135A1 (en) * 2015-02-06 2016-08-11 Unity Biotechnology, Inc. Compounds and uses in treatment of senescence-associated conditons

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
RU2258170C2 (ru) 2001-04-11 2005-08-10 Сумитомо Метал Индастриз, Лтд. Резьбовое соединение для стальных труб и способ обработки его поверхности
US9804295B2 (en) 2005-05-05 2017-10-31 Novartis Ag Ophthalmic devices for sustained delivery of active compounds
WO2009094466A2 (en) 2008-01-22 2009-07-30 University Of Florida Research Foundation, Inc. Contact lenses for extended release of bioactive agents containing diffusion attenuators
US8353856B2 (en) 2008-11-05 2013-01-15 Abbott Medical Optics Inc. Glaucoma drainage shunts and methods of use
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
RU2015149680A (ru) * 2013-04-21 2017-05-24 Йеда Ресеарч Энд Девелопмент Ко. Лтд. Агенты для подавления активности и/или снижения количества bcl-xl и/или bcl-w
WO2015017536A1 (en) 2013-07-31 2015-02-05 The Board Of Trustees Of The Leland Stanford Junior University Method and system for evaluating progression of age-related macular degeneration
US20150038140A1 (en) 2013-07-31 2015-02-05 Qualcomm Incorporated Predictive mobility in cellular networks
IL286427B2 (en) 2014-01-28 2024-08-01 Mayo Found Medical Education & Res Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
US20180000816A1 (en) * 2015-02-06 2018-01-04 Unity Biotechnology, Inc. Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
US20180193458A1 (en) * 2015-07-08 2018-07-12 Unity Biotechnology, Inc. Compositions and methods for treating senescence-associated diseases and disorders
WO2017101851A1 (en) * 2015-12-18 2017-06-22 Unity Biotechnology, Inc. Acylsulfonamide derivatives for treating senescence-associated diseases and disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012103059A2 (en) * 2011-01-25 2012-08-02 The Regents Of The University Of Michigan Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
WO2014113413A1 (en) * 2013-01-16 2014-07-24 The Regents Of The University Of Michigan Bcl-2bcl-xl inhibitors and therapeutic methods using the same
WO2016127135A1 (en) * 2015-02-06 2016-08-11 Unity Biotechnology, Inc. Compounds and uses in treatment of senescence-associated conditons

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115568281A (zh) * 2021-05-04 2023-01-03 福森生物科技有限公司 一种含有咪唑啉衍生物化合物作为有效成分的用于治疗黄斑变性的药物组合物
WO2024051741A1 (zh) * 2022-09-06 2024-03-14 西藏海思科制药有限公司 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用

Also Published As

Publication number Publication date
WO2019033119A1 (en) 2019-02-14
AU2018314280B2 (en) 2023-07-20
AU2023251388A1 (en) 2023-11-02
JP2023100864A (ja) 2023-07-19
AU2018314280A1 (en) 2020-02-27
JP2020530470A (ja) 2020-10-22
MX2025004366A (es) 2025-05-02
MX2020001644A (es) 2020-07-13
EP4234025A3 (en) 2024-04-24
EP3441069A1 (en) 2019-02-13
AU2023251388B2 (en) 2024-12-12
EP4234025A2 (en) 2023-08-30
CA3072673A1 (en) 2019-02-14
RU2020109987A (ru) 2021-09-13
EP3441069B1 (en) 2023-04-05
JP7278257B2 (ja) 2023-05-19

Similar Documents

Publication Publication Date Title
AU2023251388B2 (en) Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
US11865123B2 (en) Methods of inhibiting pathological angiogenesis
Scuderi et al. Pigment dispersion syndrome and pigmentary glaucoma: a review and update
De Keyser et al. Selective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients
Davids et al. Ab interno canaloplasty (ABiC)—12-month results of a new minimally invasive glaucoma surgery (MIGS)
EP3886858B1 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
TW201440774A (zh) 眼底疾患治療劑
Hu et al. Efficacy of the XEN gel stent on intraocular pressure lowering in East Asian eyes
Li et al. Lacrimal duct occlusion is associated with infectious keratitis
Wood et al. Rare corneal complication following selective laser trabeculoplasty
Galloway et al. The Ageing Eye
RU2815482C2 (ru) Лечение глазных болезней типа дегенерации желтого пятна, глаукомы и диабетической ретинопатии с помощью лекарственных средств, устраняющих стареющие клетки
HK40032714A (en) Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
Narayanaswamy et al. Randomized, controlled trial of a sustained delivery formulation of 5-fluorouracil for the treatment of failing blebs
Dikmetas et al. Glaucoma and ocular surface
ALBÉ et al. Ocular diseases of importance to the refractive surgeon
Vallabh et al. Pathology of Glaucoma
Ji et al. Long-term Efficacy of Compound Trabeculectomy in the Treatment of Uveitic Glaucoma: A Retrospective Cohort Study
Jeganathan et al. Challenges in the management of glaucoma in a patient with severe ocular surface disease: a case report
Patel Development and Evaluation of a Nanomicellar Eye Drop Formulation of Dexamethasone for Posterior Uveitis
EL-Kasaby Internal Limiting Membrane Peeling for Diffuse Tractional Diabetic Macular Oedema
HK40061312B (en) Compounds for treatment of eye diseases associated with excessive vascularisation
HK40061312A (en) Compounds for treatment of eye diseases associated with excessive vascularisation
Singla et al. A randomized controlled prospective study to assess the role of subconjunctival bevacizumab in preventing recurrence in primary pterygium excision
Arthurs et al. ANNUAL INDEX'INDEX ANNUEL

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40032714

Country of ref document: HK